small molecule

GOCOVRI

AMANTADINE HYDROCHLORIDE

Loss of exclusivityAugust 2038latest FDA-listed patent expiry
CompanySupernus PharmaceuticalsView the full company profile on CliffBio

Drug detail

Brand nameGOCOVRI
Active ingredientAMANTADINE HYDROCHLORIDE
StrengthEQ 68.5MG BASE
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2017
Marketing statusRX

Listed patents

PatentExpiresType
11065213August 2038product
12233033August 2038use U-2224
11077073August 2038use U-3180
10154971December 2034use U-2459
10646456June 2034use U-2808
11903908June 2034use U-3822
9867793December 2030use U-2106
9867792December 2030use U-2106
9867791December 2030use U-2106
9877933December 2030use U-2224
8741343December 2030use U-2106
11197835December 2030use U-2106
8389578January 2028use U-2105

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

GOCOVRI patent cliff — loss of exclusivity August 2038 | CliffBio